This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Clinton Edward Leysath: Innovator in Targeted Delivery Systems
Introduction
Clinton Edward Leysath is a notable inventor based in College Station, TX (US). He has made significant contributions to the field of biotechnology, particularly in the development of targeted delivery systems for therapeutic compounds. His innovative work has the potential to enhance the efficacy of treatments for various diseases.
Latest Patents
Leysath holds a patent for an invention titled "Engineered anthrax lethal toxin for targeted delivery." This patent describes methods and systems for the targeted delivery of a compound to a target cell that over-expresses two different proteinases. The invention involves administering two modified protective antigen proteins, which form a hetero-oligomer upon cleavage by distinct proteinases. This allows the compound to bind to the hetero-oligomer and be translocated into the target cell. Leysath's patent is a testament to his innovative approach in the field.
Career Highlights
Clinton Edward Leysath is associated with the United States of America, as represented by the Secretary, Department of Health and Human Services. His work in this esteemed organization highlights his commitment to advancing health-related technologies. With a focus on targeted delivery systems, Leysath has positioned himself as a key player in the biotechnology sector.
Collaborations
Leysath has collaborated with notable colleagues, including Damilola Daniel Phillips and Stephen H Leppla. These collaborations have likely contributed to the success of his research and innovations in the field.
Conclusion
Clinton Edward Leysath is a distinguished inventor whose work in targeted delivery systems has the potential to revolutionize therapeutic approaches. His patent and collaborations reflect his dedication to advancing biotechnology for improved health outcomes.
